Humacyte, Inc. (HUMA) stock
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.50−0.04 (-7.27%)
Close on Nov 17, 2026Market cap $139.18MP/E –Yield –
Humacyte price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Humacyte's price to sales ratio was 77.5× on Nov 11, 2026, against 136.5× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 77.5× | −19.6 |
| 2025 | Dec 31, 2025 | 97.1× | – |
See a number that looks wrong?